Logo Image
|Videos|December 15, 2016

What is the Prevalence of Powassan Virus in Humans in the US?

Holly Frost, MD, pediatrics physician scientist at the Marshfield Clinic Research Foundation, in Minocqua, Wisconsin, discusses the prevalence of Powassan virus in humans in the United States.

Holly Frost, MD, pediatrics physician scientist at the Marshfield Clinic Research Foundation, in Minocqua, Wisconsin, discusses the prevalence of Powassan virus in humans in the United States.

Interview Transcript (slightly modified for readability)

“This was the first study that looked at the prevalence of Powassan virus in humans. We found that, of patients presenting in the Upper-Midwest with suspected tick-borne disease, about 10% of patients had serologic evidence of Powassan virus.

We also looked at patients who were presenting just for routine chemistry screening, and we found that about 4% of those patients had serologic evidence of a past Powassan virus infection. We know that the prevalence in humans is likely to be higher than what we had previously estimated, because the [virus’s] prevalence in ticks is growing; so, about 7% of Ixodes scapularis ticks in some endemic regions now carry Powassan virus, and up to 90% of mammals in some endemic regions of New England have serologic evidence of Powassan virus.”

Related to this article

View more
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Read more
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Read more
Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Read more
ID Week Highlights Part 1
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Read more